drugset / Trial / NCT06414434
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
Timeline
- Start
- 2024-09-30
- Primary completion
- 2027-01-15
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BTX-A51 | Small molecule | 21 mg | Oral |
| Subject | BTX-A51 | Small molecule | 30 mg | Oral |